Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
111 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04047862 | Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors | completed | Phase 1 | 446 | BeiGeneINDUSTRY | 6 | Aug 22, 2025 | clinicaltrials |
| NCT03708328 | A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors | completed | Phase 1 | 134 | Hoffmann-La RocheINDUSTRY | 6 | Aug 20, 2025 | clinicaltrials |
| NCT03059823 | A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors | completed | Phase 1 | 325 | Incyte CorporationINDUSTRY | 16 | Aug 3, 2025 | clinicaltrials |
| NCT03307629 | Safety and Tolerability of NOX66 in Combination With Palliative Radiotherapy in Patients With Late-Stage Prostate Cancer | completed | Phase 1 | 25 | Noxopharm LimitedINDUSTRY | 3 | Jul 29, 2025 | clinicaltrials |
| NCT05487235 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 57 | Genentech, Inc.INDUSTRY | 6 | Jul 3, 2025 | clinicaltrials |
| NCT04870112 | A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer(SCope-D1) | terminated | Phase 1 | 18 | AstraZenecaINDUSTRY | 4 | Apr 17, 2025 | clinicaltrials |
| NCT03179436 | Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001) | completed | Phase 1 / Phase 2 | 415 | Merck Sharp & Dohme LLCINDUSTRY | 16 | Apr 8, 2025 | clinicaltrials |
| NCT03212404 | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | active not recruiting | Phase 1 | 272 | Checkpoint Therapeutics, Inc.INDUSTRY | 9 | Feb 3, 2025 | clinicaltrials |
| NCT03948763 | A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001) | terminated | Phase 1 | 70 | Merck Sharp & Dohme LLCINDUSTRY | 7 | Jan 28, 2025 | clinicaltrials |
| NCT02610361 | Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors | completed | Phase 1 | 131 | BeiGeneINDUSTRY | 2 | Dec 27, 2024 | clinicaltrials |
| NCT03379259 | Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 39 | BeiGeneINDUSTRY | 3 | Oct 26, 2024 | clinicaltrials |
| NCT04049513 | ENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy)(ENABLE-1) | active not recruiting | Phase 1 | 30 | Malaghan Institute of Medical ResearchOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT01798004 | Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma | completed | Phase 1 | 150 | Children's Oncology GroupNETWORK | 4 | Jul 15, 2024 | clinicaltrials |
| NCT04284761 | A Study to Establish the Feasibility of Biolen for the Local Delivery of Bicalutamide in Patients With Prostate Cancer(Biolen-PC) | completed | Phase 1 | 17 | Alessa Therapeutics Inc.INDUSTRY | 3 | Jun 24, 2024 | clinicaltrials |
| NCT04625907 | FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma(FaR-RMS) | recruiting | Phase 1 / Phase 2 | 1,672 | University of BirminghamOTHER | 20 | May 23, 2024 | clinicaltrials |
| NCT03980314 | A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete Resection | completed | Phase 1 | 261 | Bristol-Myers SquibbINDUSTRY | 14 | Dec 15, 2023 | clinicaltrials |
| NCT01348919 | Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 11 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 2 | Jun 28, 2023 | clinicaltrials |
| NCT04029922 | Study of MT-5111 in HER2-positive Solid Tumors(MT-5111) | terminated | Phase 1 | 50 | Molecular Templates, Inc.INDUSTRY | 3 | Jun 18, 2023 | clinicaltrials |
| NCT05242146 | GB5121 in Adult Patients With Relapsed/Refractory CNS Lymphoma(STAR CNS) | terminated | Phase 1 | 12 | GB005, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.INDUSTRY | 6 | Jun 13, 2023 | clinicaltrials |
| NCT04311710 | A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types(CheckMate 76U) | terminated | Phase 1 | 21 | Bristol-Myers SquibbINDUSTRY | 3 | Feb 24, 2023 | clinicaltrials |
| NCT04049617 | Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Evixapodlin (Formerly GS-4224) in Participants With Advanced Solid Tumors | terminated | Phase 1 | 18 | Gilead SciencesINDUSTRY | 2 | Oct 6, 2022 | clinicaltrials |
| NCT02926768 | Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors | completed | Phase 1 | 136 | Checkpoint Therapeutics, Inc.INDUSTRY | 5 | Jul 26, 2022 | clinicaltrials |
| NCT03655613 | APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC | terminated | Phase 1 / Phase 2 | 20 | Apollomics (Australia) Pty. Ltd.INDUSTRY | 2 | May 6, 2022 | clinicaltrials |
| NCT02343120 | Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies | completed | Phase 1 / Phase 2 | 385 | BeiGeneINDUSTRY | 6 | Apr 28, 2022 | clinicaltrials |
| NCT04035473 | A Study to Determine the Bioequivalence of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel | completed | Phase 1 | 42 | Athenex, Inc.INDUSTRY | 3 | Apr 13, 2022 | clinicaltrials |
| NCT02660034 | The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors | completed | Phase 1 | 229 | BeiGeneINDUSTRY | 6 | Dec 6, 2021 | clinicaltrials |
| NCT02407990 | Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumors | completed | Phase 1 | 451 | BeiGeneINDUSTRY | 5 | Nov 17, 2021 | clinicaltrials |
| NCT02521870 | A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | terminated | Phase 1 / Phase 2 | 241 | Dynavax Technologies CorporationINDUSTRY | 4 | Aug 3, 2021 | clinicaltrials |
| NCT02715531 | A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors | completed | Phase 1 | 243 | Hoffmann-La RocheINDUSTRY | 7 | Jul 9, 2021 | clinicaltrials |
| NCT00109707 | A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies | completed | Phase 1 / Phase 2 | 507 | Novartis PharmaceuticalsINDUSTRY | 22 | Jun 29, 2021 | clinicaltrials |
| NCT03291288 | Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics) | completed | Phase 1 | 32 | Daiichi SankyoINDUSTRY | 4 | May 14, 2021 | clinicaltrials |
| NCT01482156 | Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors | completed | Phase 1 | 46 | Novartis PharmaceuticalsINDUSTRY | 7 | Dec 21, 2020 | clinicaltrials |
| NCT01278849 | An Open-label, Dose Escalation Study to Assess the Pharmacokinetics of of ASA404 in Adult Cancer Patients With Impaired Hepatic Function | terminated | Phase 1 | 5 | Novartis PharmaceuticalsINDUSTRY | 2 | Dec 9, 2020 | clinicaltrials |
| NCT01189929 | A Study of Gemcitabine and Demcizumab (OMP-21M18) With or Without Abraxane® as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic Cancer | completed | Phase 1 | 57 | OncoMed Pharmaceuticals, Inc.INDUSTRY | 3 | Sep 9, 2020 | clinicaltrials |
| NCT01189942 | A Study of FOLFIRI Plus OMP-21M18 as 1st or 2nd-line Treatment in Subjects With Metastatic Colorectal Cancer | completed | Phase 1 | 18 | OncoMed Pharmaceuticals, Inc.INDUSTRY | 2 | Sep 9, 2020 | clinicaltrials |
| NCT01189968 | A Study of Carboplatin and Pemetrexed Plus Demcizumab (OMP-21M18) in Subjects With Non-Squamous Non-Small Cell Lung Cancer | completed | Phase 1 | 50 | OncoMed Pharmaceuticals, Inc.INDUSTRY | 3 | Sep 9, 2020 | clinicaltrials |
| NCT02512237 | A Dose-escalation Study of ARX788, IV Administered in Subjects With Advanced Cancers With HER2 Expression | terminated | Phase 1 | 9 | Zhejiang Medicine Co., Ltd.INDUSTRY | 2 | Jun 5, 2020 | clinicaltrials |
| NCT02624986 | A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants | terminated | Phase 1 / Phase 2 | 25 | Hoffmann-La RocheINDUSTRY | 5 | May 18, 2020 | clinicaltrials |
| NCT02521376 | Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function | completed | Phase 1 | 56 | Gilead SciencesINDUSTRY | 3 | Jul 26, 2019 | clinicaltrials |
| NCT01292603 | A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia | completed | Phase 1 | 240 | Hoffmann-La RocheINDUSTRY | 19 | Dec 19, 2018 | clinicaltrials |
| NCT01950273 | Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Follicular Lymphoma | completed | Phase 1 | 95 | Boehringer IngelheimINDUSTRY | 13 | Sep 5, 2018 | clinicaltrials |
| NCT02738970 | A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Healthy Male Participants and Women With Early Breast Cancer (EBC) | completed | Phase 1 | 88 | Hoffmann-La RocheINDUSTRY | 1 | Jun 12, 2018 | clinicaltrials |
| NCT00334646 | Cyclophosphamide Drug Interaction Study In Cancer Patients | terminated | Phase 1 | 25 | GlaxoSmithKlineINDUSTRY | 3 | Nov 17, 2017 | clinicaltrials |
| NCT01110031 | Ofatumumab Cardiac Repolarization (QTc) Study in Fludarabine-Refractory Chronic Lymphocytic Leukemia Subjects | completed | Phase 1 | 12 | GlaxoSmithKlineINDUSTRY | 3 | Nov 13, 2017 | clinicaltrials |
| NCT01299701 | A Single Center Study to Characterize the Absorption, Distribution, Metabolism and Excretion (ADME) of ASA404 After a Single Infusion in Patients With Solid Tumors | terminated | Phase 1 | 7 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 14, 2017 | clinicaltrials |
| NCT00800436 | A Dose-Finding Study of Subcutaneous Herceptin (Trastuzumab) in Healthy Male Volunteers and Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Females | completed | Phase 1 | 66 | Hoffmann-La RocheINDUSTRY | 2 | Dec 16, 2016 | clinicaltrials |
| NCT01493336 | A Study of Capecitabine Rapid Disintegrating Tablets (RDT) Versus Commercial Xeloda in Patients With Solid Tumours | completed | Phase 1 | 37 | Hoffmann-La RocheINDUSTRY | 3 | Nov 2, 2016 | clinicaltrials |
| NCT01851824 | A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy | completed | Phase 1 | 9 | Hoffmann-La RocheINDUSTRY | 9 | Nov 2, 2016 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials